(Press-News.org) WHAT:
HIV is coated in sugars that usually hide the virus from the immune system. Newly published research reveals how one broadly neutralizing HIV antibody actually uses part of the sugary cloak to help bind to the virus. The antibody binding site, called the V1/V2 region, represents a suitable HIV vaccine target, according to the scientists who conducted the study. In addition, their research reveals the detailed structure of the V1/V2 region, the last part of the virus surface to be visualized at the atomic level.
The study was led by Peter D. Kwong, Ph.D., chief of the Structural Biology Section of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Some people who have been infected with HIV for several years begin to make antibodies that can neutralize a wide range of virus strains. These broadly neutralizing antibodies bind to one of four sites on the virus. One site involves a sugar at a spot called amino acid residue 160. (Amino acids are the building blocks of proteins.) The sugar is located on the protein-based spikes that jut out of the surface of HIV.
The new study demonstrates how a broadly neutralizing HIV antibody called PG9 disarms the virus by grabbing hold of the sugar at residue 160, along with part of a second sugar and a short string of amino acid residues in the V1/V2 region of an HIV spike.
Similarly, a separate, recently published report* from the IAVI Neutralizing Antibody Center at The Scripps Research Institute showed how a different broadly neutralizing HIV antibody also binds to the virus via two sugars and a string of amino acid residues. Taken together, these two studies indicate that in some cases, the combination of viral sugars and amino acids can form the binding site for broadly neutralizing HIV antibodies.
The new study may also help scientists who are examining data from the clinical trial of the first HIV vaccine to demonstrate effectiveness in people (http://www.niaid.nih.gov/news/newsreleases/2009/Pages/ThaiVaxStudy.aspx). Recent analyses of blood samples from that trial showed that study participants who were vaccinated and then developed antibodies to the V1/V2 region were less likely to become infected. Although the role of those antibodies in protection against HIV is unknown, this finding underscores how understanding antibody-V1/V2 binding could aid the design of a more effective HIV vaccine.
### Collaborators on the new study included investigators from the University of Washington; The Scripps Research Institute; the National Institute of Diabetes and Digestive and Kidney Diseases at NIH; The Duke Human Vaccine Institute; Duke University Medical Center; Tumaini University; the Kilimanjaro Reproductive Health Programme; the Ragon Institute of MGH, MIT, and Harvard; the International AIDS Vaccine Initiative; and the University of Maryland School of Medicine.
ARTICLES:
JS McLellan et al., Structure of HIV-1 gp120 V1V2 domain with broadly neutralizing antibody PG9. Nature DOI: 10.1038/nature10696 (2011).
*R Pejchal et al., A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science DOI: 10.1126/science.1213256 (2011).
WHO:
Gary J. Nabel, M.D., Ph.D., coauthor and director of the NIAID Vaccine Research Center, and Jason S. McLellan, Ph.D., first coauthor and research fellow in the NIAID Vaccine Research Center, are available for interviews.
CONTACT:
To schedule an interview, please contact Laura Sivitz Leifman, (301) 402-1663, niaidnews@niaid.nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.
Scientists determine how antibody recognizes key sugars on HIV surface
NIH-led study advances HIV vaccine research
2011-11-24
ELSE PRESS RELEASES FROM THIS DATE:
The Connection Between Traumatic Brain Injuries and Auto Accidents
2011-11-24
Article provided by McCann Schaible & Wall, LLC Visit us at www.mswattorneys.com
Traumatic brain injuries, or TBIs, are some of the most severe traumas people can experience. Often, TBIs leave patients with lifelong side effects that affect their ability to function in their work and personal lives. Unfortunately, one of the most prevalent causes of TBI is also one of the most common American behaviors: driving.
Motor vehicle accidents are the second-leading cause of TBIs in the United States, accounting for over 17 percent of brain injuries, and are the leading ...
Mice with fewer insulin-signaling receptors don't live longer
2011-11-24
SAN ANTONIO (Nov. 23, 2011) — Scientists studying longevity thought it might be good to lack a copy of a gene, called IGF1 receptor, that is important in insulin signaling. Previous studies showed invertebrates that lacked the copy lived longer, even if their bodies were less responsive to insulin, the hormone that lowers blood sugar.
A new study from The University of Texas Health Science Center San Antonio challenges this. Knocking out one copy of the gene failed to increase the life span of male mice, and it only modestly increased the life span of female littermates. ...
Vitamin D–fortified yoghurt improves cholesterol levels and heart disease biomarkers for diabetics
2011-11-24
People with diabetes are known to have an increased risk of heart disease. New research published in BioMed Central's open access journal BMC Medicine shows that regular consumption of a vitamin D-fortified yoghurt drink improves cholesterol levels and biomarkers of endothelial dysfunction, a precursor of heart disease, in diabetics.
Not having enough vitamin D affects the inner lining of blood vessels (endothelial cells) eventually leading to atherosclerosis and cardiovascular disease. Endothelial dysfunction can be measured by the increased levels of a set of biomarkers, ...
Dreaming takes the sting out of painful memories
2011-11-24
They say time heals all wounds, and new research from the University of California, Berkeley, indicates that time spent in dream sleep can help.
UC Berkeley researchers have found that during the dream phase of sleep, also known as REM sleep, our stress chemistry shuts down and the brain processes emotional experiences and takes the painful edge off difficult memories.
The findings offer a compelling explanation for why people with post-traumatic stress disorder (PTSD), such as war veterans, have a hard time recovering from painful experiences and suffer reoccurring ...
Employment Agreements: When to Use Non-Competition and Non-Solicitation Clauses
2011-11-24
In today's marketplace, employees change jobs frequently as certain skill sets are in high demand. Many Utah businesses do not adequately protect themselves for the potential departures of these special high performing employees.
Recently, Ford Motor Company filed suit against a past marketing executive who, after leaving Ford, took a job as President of a large Toyota distributor. Ford's concerns included the possibility of its former employee taking valuable business knowledge and giving that to a direct competitor. The former Ford employee had signed a non-compete ...
Simple night time airflow control device eases persistent asthma symptoms
2011-11-24
A simple device that filters out airborne asthma triggers during sleep can ease persistent symptoms of the condition during the day and improve quality of life, suggests research published online in Thorax.
Temperature controlled laminar airflow treatment, or TLA for short, delivers a constant, slightly cooled airflow in the patient's breathing area, which displaces warmer air containing irritants and allergens, such as house dust mite and pet hairs.
The aim is to stave off the abnormal immune response that triggers a systemic allergic reaction, including the airway ...
Doctors could learn from Shakespeare’s deep understanding of mind-body connection
2011-11-24
Shakespeare was a master at portraying profound emotional upset in the physical symptoms of his characters, and many modern day doctors would do well to study the Bard to better understand the mind-body connection, concludes an analysis of his works, published in Medical Humanities.
Kenneth Heaton, a medical doctor and extensively published author on William Shakespeare's oeuvre, systematically analysed 42 of the author's major works and 46 of those of his contemporaries, looking for evidence of psychosomatic symptoms.
He focused on sensory symptoms other than those ...
Firefighters more likely to be injured exercising than putting out fires
2011-11-24
Firefighters are more likely to be injured while exercising than while putting out fires, suggests research published online in Injury Prevention.
But carrying patients is the task most likely to require time off work, the study shows.
Combined firefighting and emergency medical services have one of the highest workplace injury and death rates in the US.
The authors looked at data for injuries sustained while at work for 21 fire stations serving the metropolitan area of Tucson, Arizona between 2004 and 2009.
The 650 employees included firefighters, paramedics, ...
Law Enforcement Officials Turning to Facebook as a Crime Fighting Tool
2011-11-24
Increased participation on social networking sites has resulted in law enforcement officers in New York and across the nation to turn to sites such as Facebook for information and evidence.
Officers can use information found on individual users' pages to track their location, view photos and other personal information shared on their profiles. And it is not just information made public by the users' privacy settings. Facebook's privacy agreement allows Facebook to share information posted on the website with law enforcement officials if there is a good faith belief that ...
Researchers develop method for advancing development of antipsychotic drugs
2011-11-24
RICHMOND, Va. (Nov. 23, 2011) – Researchers interested in the treatment of schizophrenia and dementia have clarified how antipsychotic drugs that target a complex of two receptors at the surface of cells in the brain work, according to a new study published online Nov. 23 in the journal Cell.
The multidisciplinary team included researchers from the Virginia Commonwealth University School of Medicine, together with the Mount Sinai School of Medicine in New York and the University of Maryland School of Pharmacy in Baltimore. In an earlier, but related study, the Mount Sinai ...
LAST 30 PRESS RELEASES:
Dr. Gianluca Ianiro wins a prestigious grant from the European Research Council (ERC)
‘Rogue’ DNA rings reveal earliest clues to deadly brain cancer’s growth
Clinical study deepens understanding of mesothelioma and opens the door to potential treatment options
New study and major data updates expand the Kids First data ecosystem
Seaweed snare: Sargassum stops sea turtle hatchlings in their tracks
Scientists uncover key to decoupling economic growth from pollution in developing countries
Frailty fuels gut imbalance and post-surgery gastrointestinal risks
BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors
Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC
Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds
Video assisted thoracoscopy surgery reduces mortality by 21 percent compared to lobectomy
NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC
EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC
Training to improve memory
Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?
Black youth, especially Black girls, use mental health services less than their White peers
Canada must protect youth from sports betting advertising
First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer
Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial
Higher blood pressure in childhood linked to earlier death from heart disease in adulthood
AI helped older adults report accurate blood pressure readings at home
High blood pressure in childhood and premature cardiovascular disease mortality
Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations
Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC
Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy
FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC
Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study
New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients
Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds
COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC
[Press-News.org] Scientists determine how antibody recognizes key sugars on HIV surfaceNIH-led study advances HIV vaccine research